Is Omeros (USA Stocks:OMER) finally getting endorsement from retail investors?

OMER Stock  USD 3.58  0.33  10.15%   
Omeros Tangible Asset Value is relatively stable at the moment as compared to the past year. Omeros reported last year Tangible Asset Value of 482.16 Million. As of 03/06/2023, Working Capital is likely to grow to about 243.4 M, while Average Equity is likely to drop (163.3 M). While some baby boomers are getting worried about pharmaceuticals space, it is reasonable to sum up Omeros. We will evaluate if Omeros shares are reasonably priced going into April. Here I will also sum up some technical and fundamental indicators that Omeros investors should consider in April.
Published over two weeks ago
View all stories for Omeros | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Rifka Kats

This firm is undervalued at 4.72 per share with modest projections ahead.
Omeros holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 0.8706, which implies possible diversification benefits within a given portfolio. Let's try to break down what Omeros's beta means in this case. Omeros returns are very sensitive to returns on the market. As the market goes up or down, Omeros is expected to follow. Although it is vital to follow Omeros current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing price patterns. Our philosophy towards forecasting future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Omeros expected return of 1.42 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Omeros potential upside, and the relationship between the total risk alpha and kurtosis to analyze future returns on Omeros.

How important is Omeros's Liquidity

Omeros financial leverage refers to using borrowed capital as a funding source to finance Omeros ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Omeros financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Omeros's total debt and its cash.

How does Omeros utilize its cash?

To perform a cash flow analysis of Omeros, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Omeros is receiving and how much cash it distributes out in a given period. The Omeros cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Omeros Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Omeros reported last year Net Cash Flow from Operations of (86.48 Million)

What is driving Omeros Investor Appetite?

Omeros owns a total of sixty-two million seven hundred thirty thousand outstanding shares. 30% of Omeros outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
 2022 2023 (projected)
Interest Expense22.62 M18.58 M
Gross Profit33.76 M30.5 M

Ownership Breakdown

Retail Investors
Retail Investors63.36

Our take on Omeros small fall

Latest semi deviation is at 4.54. Omeros is displaying above-average volatility over the selected time horizon. Investors should scrutinize Omeros independently to ensure intended market timing strategies are aligned with expectations about Omeros volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Omeros' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Omeros' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Bottom Line

While many other companies in the biotechnology industry are either recovering or due for a correction, Omeros may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 6th of March 2023, our ongoing 90 days advice on the enterprise is Strong Hold. We believe Omeros is currently undervalued with average chance of financial distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Omeros. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to